- Home
- ANAB vs FCBC Comparison
ANAB vs FCBC Comparison
Compare ANAB & FCBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- FCBC
- Stock Information
- Founded
- ANAB 2005
- FCBC 1874
- Country
- ANAB United States
- FCBC United States
- Employees
- ANAB N/A
- FCBC N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- FCBC Major Banks
- Sector
- ANAB Health Care
- FCBC Finance
- Exchange
- ANAB Nasdaq
- FCBC Nasdaq
- Market Cap
- ANAB 759.5M
- FCBC 758.2M
- IPO Year
- ANAB 2017
- FCBC 1992
- Fundamental
- Price
- ANAB $18.59
- FCBC $40.22
- Analyst Decision
- ANAB Buy
- FCBC Hold
- Analyst Count
- ANAB 12
- FCBC 1
- Target Price
- ANAB $41.20
- FCBC $38.00
- AVG Volume (30 Days)
- ANAB 1.4M
- FCBC 35.1K
- Earning Date
- ANAB 03-10-2025
- FCBC 01-28-2025
- Dividend Yield
- ANAB N/A
- FCBC 8.18%
- EPS Growth
- ANAB N/A
- FCBC 4.94
- EPS
- ANAB N/A
- FCBC 2.80
- Revenue
- ANAB $57,172,000.00
- FCBC $162,261,000.00
- Revenue This Year
- ANAB $229.13
- FCBC N/A
- Revenue Next Year
- ANAB N/A
- FCBC $1.86
- P/E Ratio
- ANAB N/A
- FCBC $14.36
- Revenue Growth
- ANAB 282.17
- FCBC 3.25
- 52 Week Low
- ANAB $12.21
- FCBC $31.00
- 52 Week High
- ANAB $41.31
- FCBC $49.02
- Technical
- Relative Strength Index (RSI)
- ANAB 55.28
- FCBC 37.35
- Support Level
- ANAB $12.21
- FCBC $43.61
- Resistance Level
- ANAB $21.57
- FCBC $45.28
- Average True Range (ATR)
- ANAB 1.72
- FCBC 1.07
- MACD
- ANAB 0.39
- FCBC -0.43
- Stochastic Oscillator
- ANAB 68.16
- FCBC 2.01
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.